IMMU Provides Corporate Updates and Revenue Guidance for Full Year 2025
Immunic, Inc. provided guidance that implies flat revenue for fiscal year 2025 and announced that it has not yet commenced clinical trials for its antibody pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed